Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Programmed Cell Death of Embryonic Motoneurons Triggered through the Fas Death Receptor

Cédric Raoul, Christopher E. Henderson and Brigitte Pettmann
The Journal of Cell Biology
Vol. 147, No. 5 (Nov. 29, 1999), pp. 1049-1061
Stable URL: http://www.jstor.org/stable/1619475
Page Count: 13
  • More info
  • Cite this Item
Programmed Cell Death of Embryonic Motoneurons Triggered through the Fas Death Receptor
Preview not available

Abstract

About 50% of spinal motoneurons undergo programmed cell death (PCD) after target contact, but little is known about how this process is initiated. Embryonic motoneurons coexpress the death receptor Fas and its ligand FasL at the stage at which PCD is about to begin. In the absence of trophic factors, many motoneurons die in culture within 2 d. Most (75%) of these were saved by Fas-Fc receptor body, which blocks interactions between Fas and FasL, or by the caspase-8 inhibitor tetrapeptide IETD. Therefore, activation of Fas by endogenous FasL underlies cell death induced by trophic deprivation. In the presence of neurotrophic factors, exogenous Fas activators such as soluble FasL or anti-Fas antibodies triggered PCD of 40-50% of purified motoneurons over the following 3-5 d; this treatment led to activation of caspase-3, and was blocked by IETD. Sensitivity to Fas activation is regulated: motoneurons cultured for 3 d with neurotrophic factors became completely resistant. Levels of Fas expressed by motoneurons varied little, but FasL was upregulated in the absence of neurotrophic factors. Motoneurons resistant to Fas activation expressed high levels of FLICE-inhibitory protein (FLIP), an endogenous inhibitor of caspase-8 activation. Our results suggest that Fas can act as a driving force for motoneuron PCD, and raise the possibility that active triggering of PCD may contribute to motoneuron loss during normal development and/or in pathological situations.

Page Thumbnails

  • Thumbnail: Page 
1049
    1049
  • Thumbnail: Page 
1050
    1050
  • Thumbnail: Page 
1051
    1051
  • Thumbnail: Page 
1052
    1052
  • Thumbnail: Page 
1053
    1053
  • Thumbnail: Page 
1054
    1054
  • Thumbnail: Page 
1055
    1055
  • Thumbnail: Page 
1056
    1056
  • Thumbnail: Page 
1057
    1057
  • Thumbnail: Page 
1058
    1058
  • Thumbnail: Page 
1059
    1059
  • Thumbnail: Page 
1060
    1060
  • Thumbnail: Page 
1061
    1061